UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2025	Oct. 31, 2024	Oct. 31, 2025	Oct. 31, 2024
Income Statement [Abstract]
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Oncology revenue	$ 15,035	$ 13,489	$ 29,030	$ 27,550
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Cost of oncology revenue	$ 7,262	$ 7,428	$ 15,257	$ 14,500
Research and development	2,616	1,689	4,698	3,143
Sales and marketing	1,998	1,751	3,853	3,430
General and administrative	2,974	1,889	5,544	4,416
Loss on disposal of equipment	0	0	20	0
Total costs and operating expenses	14,850	12,757	29,372	25,489
Income (loss) from operations	185	732	(342)	2,061
Other income, net	70	7	145	11
Income (loss) before provision for income taxes	255	739	(197)	2,072
Provision for income taxes	18	11	33	31
Net income (loss)	237	728	(230)	2,041
Less: net loss attributable to noncontrolling interest	31	0	61	0
Net income (loss) attributable to Company's common shares	$ 268	$ 728	$ (169)	$ 2,041
Net income (loss) per common share outstanding
basic (in dollars per share)	$ 0.02	$ 0.05	$ (0.01)	$ 0.15
diluted (in dollars per share)	$ 0.02	$ 0.05	$ (0.01)	$ 0.15
Weighted average common shares outstanding
basic (in shares)	13,791,913	13,593,766	13,758,715	13,593,766
and diluted (in shares)	14,457,837	14,016,953	13,758,715	14,029,666